# Blue Earth Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blue-earth-therapeutics

- Industry: Healthcare Specialists
- Headquarters: Oxford, UK
- Website: www.blueearththerapeutics.com
- Total disclosed funding: $77M
- Latest round: Series A (Oct 30, 2024)
- Investors on record: 5

## About

Based in the UK, Blue Earth Therapeutics Limited focuses on developing advanced radiopharmaceutical therapies designed to improve patient outcomes in oncology, particularly through targeted treatments.Founded in 2021 and headquartered in Oxford, UK, Blue Earth Therapeutics Limited is dedicated to advancing radiopharmaceutical technologies. The company raised USD 76.5 mn in Series A funding on October 30, 2024, with participation from investors such as Bracco Imaging S.p.A. and Sands Capital Ventures. This funding will support the development of radioligand therapies.Blue Earth Therapeutics specializes in the development of advanced radiopharmaceutical therapies aimed at enhancing patient outcomes in oncology. Their core product offerings include targeted radioligand therapies designed to deliver precise radiation doses to tumors while ensuring the safety of surrounding healthy organs. These therapies are crucial for treating various cancers, enabling effective tumor management without compromising patient safety. The company serves healthcare facilities and oncology specialists, offering innovative solutions that meet the growing demand for cancer treatment options in the United States and parts of Europe.Revenue for Blue Earth Therapeutics is generated through business-to-business transactions with healthcare providers and institutions utilizing their radiopharmaceutical products. The company likely engages in direct sales to hospitals and clinics, alongside potential partnerships with larger pharmaceutical distributors, integrating their therapies into existing oncology practices. Specific pricing structures for their products are not disclosed, but the company emphasizes high-value therapeutic options essential for advancing cancer care.In October 2024, Blue Earth Therapeutics Limited secured USD 76.5 mn in Series A funding, which will be utilized to support the development of their radioligand therapies. The company is likely exploring new product launches and aiming to expand into additional markets within Europe and North America. Details on specific upcoming products and target release dates have not been disclosed, but the recent funding will facilitate ongoing innovation and market penetration efforts.

## Funding rounds

- Series A, Oct 30, 2024, $77M — PBM Capital Group, Sands Capital Alternatives, Soleus Capital, Woodline Partners, Bracco Imaging S.p.A.

## Investors

- PBM Capital Group (https://capitalatlas.ai/funds/pbm-capital-group) — Series A
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series A
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series A
- Woodline Partners — Series A
- Bracco Imaging S.p.A. — Series A